What diseases does tucatinib/tucatinib treat?

Tucatinib/Tucatinib is a drug that treats certain types of cancer. They are used to treat metastatic breast cancer (MBC) and unresectable or metastatic colorectal cancer (CRC).

1. Metastatic breast cancer (MBC): Tucatinib is used in combination with trastuzumab and capecitabine. This combination therapy is suitable for adult patients with advanced breast cancer that cannot be surgically removed or has metastasized to other sites, especially those with HER2-positive breast cancer, and even those who have developed brain metastases. These patients may have previously received one or more anti-HER2-based treatment regimens. Tucatinib helps control the growth and spread of cancer cells by inhibiting the activity of the HER2 receptor.

2. Unresectable or metastatic colorectal cancer (CRC): Tucatinib is used in combination with trastuzumab for patients with RAS wild-type, HER2-positive colorectal cancer, especially those who have progressed after treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based drugs. Tucatinib helps control the progression of the disease by targeting the HER2 receptor, inhibiting the proliferation and growth of cancer cells. This is also an effective treatment option.

Tucatinib/Tucatinib is a type of targeted drug that blocks the growth and spread of cancer cells by interfering with their signaling pathways. These drugs are often used as an addition to other treatments in patients whose cancer has progressed to advanced stages or has metastasized to other sites. However, for each individual patient, the specific treatment plan should be determined based on the physician's recommendations and the patient's specific circumstances.